Clinical Trials Browser

Has results × Hematologic Neoplasms × pembrolizumab × Clear all

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Phase 2 Completed

192 enrolled 22 charts

Other hematologic neoplasm

Hematologic Neoplasms